patent.fyi
Applications  /  US 2026/0355199
United States Patent Application Publication

US 2026/0355199 A1

Published
Nov 12, 2026
Filed
Oct 3, 2023
Earliest date on the face
Oct 3, 2022
Classification
A61K 31/513
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Excising symptomatic pelvic lesions

What ifWhat if laparoscopic excision removes symptomatic endometriosis lesions?
Claim language“administering to the subject”

A laparoscope provides a view of the pelvic cavity through a small abdominal port. Surgical instruments separate visible lesions from surrounding tissue and remove them, reducing the amount of ectopic tissue.

1.1Suppressing ovarian estradiol production

What ifWhat if the administered agent blocks pituitary receptors for gonadotropin-releasing hormone to treat endometriosis pain?
Claim language“a degrader of TET protein”

An oral receptor antagonist reduces pituitary release of luteinizing hormone and follicle-stimulating hormone. The resulting drop in ovarian estradiol reduces hormonal stimulation of endometriosis lesions.

1.1Activating hepatic thyroid receptors

What ifWhat if the treatment activates hepatic thyroid hormone receptor beta to address steatohepatitis?
Claim language“inhibitor of TET protein”

An oral small molecule activates thyroid hormone receptor beta in hepatocytes. Receptor activation changes the expression of genes involved in lipid handling and reduces hepatic triglyceride accumulation.

1.1Stimulating prefrontal cortical circuits

What ifWhat if repeated magnetic pulses treat depression through stimulation of the prefrontal cortex?
Claim language“administering to the subject”

A coil positioned over the left dorsolateral prefrontal cortex produces magnetic pulses that induce electric fields in cortical tissue. Repeated sessions modulate activity in neural circuits involved in mood regulation.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary study of canine joint disease

A veterinary research protocol enrolls dogs with osteoarthritis and measurable TET activity in synovial fluid cells. An intra-articular formulation delivers a TET inhibitor to the affected joint, and a matched vehicle serves as the control. Synovial fluid samples collected before and after administration provide cells for measuring TET activity and inflammatory markers.

Component substitution

Transcript silencing with small interfering RNA

A chemically stabilized small interfering RNA replaces the protein degrader in an injectable formulation. An ionizable lipid nanoparticle carries the RNA into cells, where the RNA-induced silencing complex uses its guide strand to cleave the complementary TET transcript. Quantitative PCR and a protein immunoassay measure the resulting reductions in transcript and protein abundance.

Parameter or scale variation

Split dosing at matched weekly totals

A seven-day dosing study compares one administration on day 1 with four administrations on days 1, 3, 5, and 7. Each administration in the divided regimen contains 25 percent of the weekly amount, and both regimens use the same formulation and route. Plasma samples collected immediately before dosing and two hours afterward characterize concentration changes, and a tissue sample on day 8 measures TET protein abundance.

Combination with existing systems

Continuous delivery through an osmotic pump

An implantable osmotic pump delivers a soluble TET inhibitor through a catheter to a target tissue in an animal model. Water enters the pump through a semipermeable membrane and expands an osmotic chamber that displaces the formulation from a separate reservoir. The measured flow rate and reservoir concentration determine the delivered amount per day, and tissue collected near the catheter outlet provides a sample for measuring TET activity.

Local delivery from a biodegradable hydrogel

A biodegradable hydrogel contains a dispersed TET inhibitor and is deposited in a postoperative tissue cavity in an animal model. The gel conforms to the cavity and releases the inhibitor into adjacent tissue as the drug diffuses through the hydrated network and the matrix degrades. A bench release assay measures drug concentration in the surrounding fluid, and tissue samples collected at set distances from the gel map the local change in TET activity.

Automated or data-driven variant

Software scheduling from measured tissue response

A laboratory information system receives TET protein measurements and cell viability results from serial samples in a preclinical dosing study. A rules engine compares the measurements with protocol thresholds and selects the next dose interval from a predefined schedule. The system checks cumulative exposure and flags missing measurements for review before issuing the next dosing instruction.

Specific version of a part

Inhibiting oxidation with hydroxyglutarate

The D enantiomer of 2-hydroxyglutarate inhibits TET-catalyzed oxidation by competing with 2-oxoglutarate. A biochemical assay measures the decrease in conversion of 5-methylcytosine to 5-hydroxymethylcytosine in a DNA substrate.

Inhibiting the catalytic domain

Pyridine-2,4-dicarboxylate competes with 2-oxoglutarate at the catalytic domain of TET enzymes. A cell-free reaction containing a recombinant TET catalytic domain, ferrous iron and methylated DNA measures inhibition as a decrease in 5-hydroxymethylcytosine formation.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2016/0346306 A1
Published
Dec 1, 2016
Filed
Jan 21, 2015
Class
A61K 31/706
Document BUS 2022/0168427 A1
Published
Jun 2, 2022
Filed
Apr 8, 2020
Class
A61K 47/545
Claim 1
Document A
Document B
1.1the method comprises administering to the subject a therapeutically effective amount of a degrader of TET protein, inhibitor of TET protein, or a combination thereof, or a composition thereof.
In one aspect, the presently disclosed subject matter provides a method for treating a cancer, the method comprising administering to a subject in need of treatment thereof an effective amount of a low dose of a DNA demethylating agent and an effective amount of a poly ADP ribose polymerase (PARP) inhibitor. In particular aspects, the DNA demethylating agent is a DNA methyltransferase inhibitor (DNMTi).
A · US 2016/0346306 A1 · ¶ 6
In another aspect, a method for treating cancer is provided, comprising administering a therapeutically effective amount of the protein degradation chimera disclosed herein to a patient in need thereof.
B · US 2022/0168427 A1 · ¶ 18

An empty cell means only that no passage was reproduced there.

Statements in these documents
FLT3/ITD-expressing cells are considered one of most “unfavorable subsets” of AML with no effective treatment, suggesting the urgent need for the development of new therapies.
A · US 2016/0346306 A1 · ¶ 3
In certain aspects, the cancer is selected from the group consisting of leukemia, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), breast cancers, and ovarian cancers.
A · US 2016/0346306 A1 · ¶ 6
The present application relates generally to methods and compositions for targeted protein degradation, and more specifically, compositions that are able to induce targeted protein degradation for the treatment of cancers and other diseases.
B · US 2022/0168427 A1 · ¶ 2
These include the promiscuous degradation of the target protein in many tissues and organs, not just the tissue and organ where the target protein is involved in a disease process, which is expected to result in unwanted side effects of treatment.
B · US 2022/0168427 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355199 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355199/, SHA-256 11a99fa0caee6f626da0abef21483127d0530161eb199eadf5c04ed9934ed492
First published
Permanent addresshttps://patent.fyi/US20260355199/
Content fingerprint (SHA-256)11a99fa0caee6f626da0abef21483127d0530161eb199eadf5c04ed9934ed492
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi